VERTEX PHARMA - KALYDECO + VX-809 Analysis – PhIII Should be Successful in CF patients with Homozygous ΔF508 if….!
Vertex (VRTX) evoked an uproar when it corrected the data of its KLAYDECO/VX-809 (CFTR Potentiator + Corrector) combo PhIIb interim data in homozygous ΔF508 mutation Cystic Fibrosis (CF) pts this week. Our discussion with pulmonologists on the clinical significance of the data- 5 to 10% absolute improvement in lung function was positive. Based on our analysis and assumptions, we are optimistic that this combination can succeed in the PhIII study in CF pts with homozygous Δ508 mutation, provided the PhIII trial design.…. For more detail, please read our report released on 31th May, 2012 on Vertex titled “KALYDECO + VX-809 Analysis – PhIII Should be Successful in CF patients with Homozygous ΔF508 if….!”
COMPANIES MENTIONED
VERTEX
VERTEX
